Downloads provided by UsageCounts
doi: 10.4155/tde.13.87
pmid: 24116915
Nanobodies (Nbs) are small antibody fragments derived from camelid heavy chain antibodies through recombinant gene technology. Their exceptional physicochemical properties, possibility of humanization and unique antigen recognition properties make them excellent candidates for targeted delivery of biologically active components. Several different therapeutic approaches based on the novel camelid Nbs have been developed to treat a wide range of diseases ranging from immune, bone, blood and neurological disorders; infectious diseases and cancer. This review provides a comprehensive overview of the current state of the use of camelid-derived Nbs as novel therapeutic agents against multiple diseases.
Drug Carriers, Camelus, Protein Conformation, Chemistry, Pharmaceutical, Immunotoxins, Single-Domain Antibodies, nanobodies, Structure-Activity Relationship, Nanomedicine, Antibody Specificity, Therapeutic approaches, Animals, Humans, Immunotherapy, Camelids, New World
Drug Carriers, Camelus, Protein Conformation, Chemistry, Pharmaceutical, Immunotoxins, Single-Domain Antibodies, nanobodies, Structure-Activity Relationship, Nanomedicine, Antibody Specificity, Therapeutic approaches, Animals, Humans, Immunotherapy, Camelids, New World
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 40 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
| views | 3 | |
| downloads | 25 |

Views provided by UsageCounts
Downloads provided by UsageCounts